CoChat
Sign Up
Cited by 59Endometriosis Research and TreatmentEstrogen and related hormone effectsOvarian function and disorders

Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions

Open access
Delvoux, Bert, D'Hooghe, Thomas, Kyama, Cleophas, Koskimies, Pasi, Hermans, Rob J. J., Dunselman, Gerard A., Romano, Andrea·2014·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2013-2851
Open this paper in CoChat — free account

Abstract

CONTEXT: Endometriosis affects 10% of the women before menopause and has important personal, professional, and societal economic burdens. Because current medical treatments are aimed at reducing the symptoms only, novel therapeutic targets should be identified. Endometriosis is estrogen dependent and in some patients the endometriosis tissue is able to produce estrogens in an autocrine/paracrine manner. In a number of patients, this is the consequence of the high local activity of the 17β-hydroxysteroid-dehydrogenases (17β-HSDs), enzymes able to generate active estrogens from precursors with low activity. OBJECTIVE: The objective of the study was to identify the 17β-HSD(s) responsible for the high local generation of estrogens in endometriosis and test the possibility to inhibit these enzymes for therapeutic purposes. DESIGN: The expression of different 17β-HSDs involved in the estrogen metabolism was assessed by real-time PCR in eutopic and ectopic tissue from endometriosis patients (n=14). These biopsies had previously confirmed unbalanced local 17β-HSD activity, which caused high estrogen generation. The possibility to block the synthesis of estrogens by one inhibitor specific for type 1 17β-HSD was assessed by HPLC in tissue lysates from endometriosis tissues (n=27). RESULTS: In all but one of the patients, a high type 1 17β-HSD level is associated with the unbalanced metabolism of estrogens, leading to higher estrogen synthesis in endometriosis than in the endometrium inside the uterus. Inhibition of type 1 17β-HSD restores to various extents, depending on the patient, the correct metabolism. In 19 of 27 patients analyzed (70%), the 17β-HSD type 1 inhibitor decreased the generation of 17β-estradiol by greater than 85%. CONCLUSIONS: Inhibition of 17β-HSD type 1 can be a potential future treatment option aimed at restoring the correct metabolic balance of estrogens in endometriosis patients with increased local 17β-HSD type 1 enzyme activity.

Integrity signals

Registry

Crossref · 10.1210/jc.2013-2851

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A 17βHSD1 inhibitor suppresses conversion of estrone (E1) to estradiol (E2) in endometriosis tissue homogenates.

    “Promising results have been reported using a 17βHSD1 inhibitor to suppress conversion of E1 to E2 in endometriosis tissue homogenates [103].”

    From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [103]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Delvoux, B., D'Hooghe, T., Kyama, C., Koskimies, P., Hermans, R. J. J., Dunselman, G. A., & Romano, A.
Affiliations
  • Universitair Ziekenhuis Leuven (BE)
  • Maastricht University Medical Centre (NL)
Corresponding author
Romano, Andrea
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2014-01
Volume
99
Issue
1
Pages
276-284
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2013-2851
OpenAlex
W2059133635
Cited by
59
References
8
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 11 · 2017: 5 · 2016: 4 · 2015: 5 · 2014: 2
FWCI
4.85
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
endometriosis, 17β-hydroxysteroid dehydrogenase type 1, estrogen metabolism, enzyme inhibition, local estrogen production, endometriosis treatment, eutopic endometrium
MeSH terms
Cells, Cultured, Endometriosis, Endometrium, Enzyme Inhibitors, Estradiol, Female, Humans, Intestinal Diseases, Ovarian Diseases, Peritoneal Diseases, RNA, Messenger, 17-Hydroxysteroid Dehydrogenases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review